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Alternative splicing of transcripts in a signal-dependent manner has emerged as an important concept to ensure appropriate
expression of splice variants under different conditions. Binding of the general splicing factor U2AF to splice sites preceding
alternatively spliced exons has been suggested to be an important step for splice site recognition. For splicing to proceed,
U2AF has to be replaced by other factors. We show here that U2AF interacts with the signal-dependent splice regulator Sam68
and that forced expression of Sam68 results in enhanced binding of the U2AF65 subunit to an alternatively spliced pre-mRNA
sequence in vivo. Conversely, the rapid signal-induced and phosphorylation-dependent interference with Sam68 binding to
RNA was accompanied by reduced pre-mRNA occupancy of U2AF in vivo. Our data suggest that Sam68 can affect splice site
occupancy by U2AF in signal-dependent splicing. We propose that the induced release of U2AF from pre-mRNA provides a
regulatory step to control alternative splicing.
Citation: Tisserant A, Ko ¨nig H (2008) Signal-Regulated Pre-mRNA Occupancy by the General Splicing Factor U2AF. PLoS ONE 3(1): e1418. doi:10.1371/
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INTRODUCTION
The split structure of most protein-encoding genes in eukaryotes
requires the removal of non-coding sequences (introns) and the
joining of coding parts (exons) during mRNA maturation by
splicing [1]. By splicing precursor (pre-) mRNAs in different ways,
multiple mRNAs and proteins can be generated from a single
gene. Such alternative splicing appears as a major mechanism to
expand the coding capacity of genomes [2,3], and can explain the
increase in organismal complexity during evolution, based on
similar gene numbers [4,5]. In vertebrates, at least 30–70% of
genes give rise to alternatively spliced transcripts and splice
variants play important roles during embryonic development and
in other physiological processes [5,6]. Furthermore, aberrant
alternative splicing has been shown to underlie several patholog-
ical conditions in humans, including neurodegenerative disorders
and cancer [3,7].
Thus, appropriate generation of splice variants in the organism
must be under the control of cues that determine their expression
in different conditions. In fact, regulation of alternative splicing by
extracellular signals has increasingly emerged as a mechanism for
differential expression of gene products [8,9]. Several cellular
signaling pathways have been linked to splicing regulation. The
targets of these pathways, how these targets are modulated, and
how they are linked to the splicing machinery to regulate exon
choice are key questions - though largely unresolved ones.
In many cases, selection of alternatively spliced exons has been
shown to depend on regulatory RNA binding proteins. They
interact with either the 59 and 39 splice sites or with regulatory
sequences located in introns or exons, called splice silencer or
enhancer sequences. These proteins affect binding of spliceosomal
components to the splice sites and thus spliceosome formation [6].
A key step in spliceosome formation is the recognition of the
polypyrimidine stretch and the terminal AG dinucleotide of the 39
splice site by the 65 kDa and 35 kDa subunits, respectively, of the
spliceosome component U2AF (U2 snRNP auxiliary factor) [10].
Alternatively spliced exons are often preceded by a weak
polypyrimidine stretch (interrupted by purines) that shows weak
affinity for U2AF65. Its binding to such weak sites has been
suggested to be supported by the interaction with serine/arginine-
rich (SR) splice enhancer proteins, that in some cases is dependent
on U2AF35 [11–14].
We previously revealed the coupling of alternative splicing of
variant exons of the cell surface molecule CD44 to the Ras-MAP-
kinase pathway [15]. This evolutionary highly conserved signaling
cascade regulates several physiological processes, including cell
proliferation and survival, and its deregulation contributes to many
cancers [16,17]. The inclusion of variant (v) exons in CD44
mRNA occurs in some normal cells, e.g. in immune cells during
activation, and in the course of the progression of various tumors.
Certain CD44 variants were shown to be causally involved in
metastasis formation [18]. By studying the Ras-pathway-stimulat-
ed splicing of one these variant CD44 exons (exon v5), we
discovered the RNA-binding protein Sam68 as a splice regulator
directly modified by this pathway in mouse T-lymphoma cells
[19]. Sam68 can bind to sequences within the v5 exon and is
phosphorylated by ERK MAP-kinase at several sites upon Ras-
pathway activation. This phosphorylation is, at least in part,
necessary for inclusion of the exon in CD44 RNA in vitro and in vivo
[19].
Here we addressed the question of how the signal-dependent
modification of the Sam68 protein can affect the splicing
machinery. Our data suggest that Sam68 binds the general
splicing factor U2AF and can affect its presence on pre-mRNA in
vivo.
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We previously identifiedSam68 as a protein bindingto sequences in
the CD44 exon v5 and that regulates Ras-signaling-induced
inclusion of the exon into mRNA. Furthermore, we showed that
ERK-mediated phosphorylation of Sam68 is responsible for at least
part of the Ras-induced inclusion of the exon [19]. Thus, Sam68
may modulate the activity of the splice-regulatory complex on the
v5 exon to affect the recruitment of spliceosome components to the
surrounding splice sites. Whereas the 59 splice site downstream of
the exon (GTAAG) corresponds to the consenus sequence (GTA/
GAG), the preceding 39 splice site is predicted to be weak. As for
many alternatively spliced exons, it comprises an imperfect
polypyrimidine tract interrupted by purines (Figure S1). It is thus
predicted to be a weak target for U2AF65 binding [20,21] and
binding of U2AF65 could require support via protein-protein
interactions from RNA-binding proteins regulating v5 splicing. In
keeping with the idea that U2AF binding determines v5 exon
inclusion, conversion to a consensus polypyrimidine stretch led to
constitutive inclusion of the exon (Figure S1).
Sam68 binds the general splicing factor U2AF
To test the possibility that Sam68 could affect U2AF binding by
protein-protein interaction, we initially tested whether the two
proteins can interact in vitro. Therefore, we performed pull-down
experiments with bacterially expressed Glutathione S-transferase
(GST) fusion proteins of U2AF65 and U2AF35, respectively, and
recombinant His-tagged Sam68. As shown in Figure 1A by
immunoblotting with an anti-Sam68 antibody, both subunits of
U2AF precipitated Sam68 in a dose-dependent manner (lanes 1–4).
This was not the case when we performed the assays with the GST
portion alone (lanes 5–6), suggesting U2AF-dependent interaction.
To investigate whether Sam68 could be complexed with U2AF in
vivo, we performed co-immunoprecipitations with an anti-Sam68
antibody and lysates from LB17 mouse lymphoma cells. Immuno-
blotting with an anti-U2AF65 antibody showed that the anti-Sam68
precipitate contained U2AF65 (Figure 1B, compare lanes 2 and 3).
Precipitates from the control antibody did not show the U2AF65
band (Figure 1B, lane 1), indicating Sam68-dependent precipitation
of the protein. Treatment of the lysates prior and during
precipitation by RNase A did not interfere with co-precipitation
of U2AF65 (Figure 1C, compare lanes 2 and 3), pointing to the
associationoftheproteinsindependentofRNAbridging.Duetothe
poor sensitivity of the U2AF35 antibody available, we could not test
the presence of U2AF35 in the precipitates. Taken together these
data suggest that Sam68 can directly interact with U2AF proteins
and that Sam68 is associated with U2AF65 in vivo.
Ras-signaling-induced inclusion of CD44 exon v5 in mRNA is at
least partially dependent on phosphorylation of Sam68 by ERK
[19]. Since U2AF is a critical factor in splice site selection and given
theinteractionofSam68andU2AF,wewished totest the possibility
that the signaling-induced phosphorylation of Sam68 is linked to
splicing by affecting its interaction with U2AF. Unfortunately only a
small proportion of Sam68 can be obtained in its phosphorylated
Figure 1. Sam68 interacts with U2AF in vitro and in vivo. (A) Immunoblot analysis of GST pull-down reactions involving recombinant Sam68 and
GST-fusion proteins of U2AF65 and U2AF35. The GST protein served as a control. Immunodetection with anti-Sam68 and anti-GST antibodies is
shown in the upper and lower panels, respectively. Black bars on the left indicate positions of marker bands. (B) Co-immunoprecipitation from LB17-
lymphoma cell lysates with an anti-Sam68 antibody or a corresponding control antibody (CoAb). In lane 3, the lysate was loaded. Precipitates were
analysed by immunoblotting with an anti-U2AF65 antibody. Arrows indicate U2AF65 band; asterisks denote bands caused by immunoglobulins. (C)
Co-immunoprecipitation experiment as in (B), in the presence (+) or absence (2) of RNase A. Symbols are as in (B).
doi:10.1371/journal.pone.0001418.g001
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could not test the binding of phosphorylated Sam68 to U2AF in co-
immunoprecipitations. Therefore, we performed pull-down exper-
iments with GST-fusions of U2AF65 and U2AF35, and recombi-
nant Sam68 that was either left unphosphorylated or had been
phosphorylated by ERK in vitro. In these experiments, we could
detect no effect of Sam68 phosphorylation on the interaction of the
proteins (data not shown).
Phosphorylation of Sam68 interferes with binding
to its cognate RNA elements
We then wished to test whether phosphorylation of Sam68 by
ERK could instead affect its binding to splice-regulatory RNA
elements.
A Sam68-binding sequence in CD44 exon v5 was shown to
determine the overall level of exon inclusion [19]. We found a
secondsitecorrespondingtotheSam68consensusbindingsequence
[22] in the intron preceding the v5 exon, immediately upstream of
the putative branchpoint sequence (Figure 2A). To test whether this
second site can indeed bind Sam68, we performed electrophoretic
mobility shift assays (EMSA) involving recombinant Sam68 and
RNA oligonucleotides comprising this site or a point-mutated
version of it (A/C mutant; see Figure 2A). This mutation should
interferewithSam68binding [22].AsshowninFigure2B,theRNA
oligonucleotide comprising the wild-type sequence bound Sam68 in
a dose-dependent manner (lanes 1–4), whereas binding to the A/C-
mutated version was severely compromised (lanes 5–8), indicating
that Sam68 binds to the oligonucleotide depending on this
sequence. To test the functional relevance of this intronic Sam68
binding-element, we introduced the A/C mutation into a luciferase-
based splice-reporter minigene carrying CD44 exon v5 [15] and
transfected it into LB17 mouse lymphoma cells. In these cells
inclusion of the v5 exon in mRNA can be induced by Ras-pathway
activation upon phorbol-ester treatment [15,23]. Similar to the
mutation of the exonic Sam68 binding site [19], the A/C mutation
of the intronic Sam68 reduced the overall level of v5 exon inclusion,
whereas induction of exon inclusion by phorbol ester treatment was
still functional (Figure 2C). The same was true for a construct in
which both Sam68 binding sites were mutated (Figure 2C). These
results suggest that binding of Sam68 to these elements in the CD44
pre-mRNA determines the overall level of v5 exon inclusion in
mRNA. Signal-mediated induction of splicing, although dependent
on Sam68 [19], seems however not to depend on these sites. Could
there still be a link between Sam68 bound to these RNA elements
and splicing induction? To address this question, we initially
performed electrophoretic mobility shift assays (EMSA) employing
RNA oligonucleotides comprising either of the two Sam68 binding
elements and different amounts of either non-phosphorylated
Sam68 or of Sam68 thiophosphorylated by ERK in vitro (Figure 3).
Thestablethiophosphorylation resultsinthesameshiftinmolecular
weight (see Figure 3A) as compared to normal phophorylation and
is active in inducing v5 exon splicing in vitro [19]. So phosphorylated
Sam68 consistently shifted less radioactively labeled oligonucleotide
as compared to non-phosphorylated Sam68, both with the exonic
element (Figure 3B, lanes 2–5) and the intronic element probe
(Figure 3B, lanes 7–10). This result suggests that phosphorylation of
Sam68 by ERK interferes with the ability of Sam68 to bind its
cognate RNA binding elements in vitro.
Signaling-induced inhibition of Sam68 binding to
pre-mRNA in vivo
Based on these results one would postulate that stimulation of
the Ras-Erk MAP-kinase cascade results in less Sam68 bound to
pre-mRNA carrying such elements. To test this hypothesis in vivo,
we adapted the ribonucleoprotein (RNP) immunoprecipitation
technique [24] to determine the occupancy of the corresponding
CD44 pre-mRNA region by Sam68. Analogous to the detection of
Figure 2. Intronic and exonic Sam68 binding sites affect CD44 v5
exon inclusion. (A) Scheme indicating positions of the Sam68 binding
sites (black oval and box, respectively) in CD44 exon v5 (open box) and
the upstream intron (line). The Sam68 consensus binding site in the
wild-type RNA sequence used for the electrophoretic mobility shift
assay (EMSA) in panel B is boxed. The mutated nucleotide of the A/C
mutant is indicated in red. (B) EMSA using recombinant Sam68 and
radioactively labeled RNA oligonucleotide probes comprising either the
wild-type or the A/C-mutant version of the intronic Sam68 binding site
(see panel A). (C) v5-luciferase fusion activity from LB17 lymphoma cells
transfected with different pETv5luc splice-reporter genes [15]. They
were mutated for either the exonic (L/CC mutant [19]), the intronic (A/C
mutant), or both Sam68 binding sites (double mutant). Cells were
treated with 12-o-tetradecanoylphorbol-13-acetate (TPA, 40 ngml
21)
(+) or with DMSO (solvent control) (2) for 6h prior to lysis and
measurement of luciferase activity. Error bars indicate standard
deviations from three independent transfections.
doi:10.1371/journal.pone.0001418.g002
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method detects RNA-protein interactions in vivo. Employing
reversible formaldehyde crosslinking and high-stringency immu-
noprecipitation, specific RNA fragments associated with a given
protein are identified by reverse transcription followed by PCR
(RT-PCR). We initially showed that a fragment from endogenous
CD44 pre-mRNA spanning the v5 exon and 110 nucleotides of
the upstream intron sequence could be amplified from precipitates
of an anti-Sam68 antibody, but not from precipitates of a
corresponding control antibody (Figure 4A). This result indicates
specific precipitation of the RNA fragment and suggests the
occupancy of this CD44 pre-mRNA region by Sam68 in vivo. Since
only a small proportion of endogenous CD44 pre-mRNA
molecules include CD44 exon v5 upon phorbol-ester stimulation
in our lymphoma cell model [23], changes in protein binding to
this minority of molecules would be difficult to detect. To
overcome this issue, we transiently transfected the LB17
lymphoma cells with a minigene carrying the v5 exon and
surrounding intron sequences, flanked by insulin exons (pETv5).
Upon phorbol-ester treatment, the majority of pre-mRNA
molecules from this construct include the v5 exon [23]. As shown
in Figure 4B, the anti-Sam68 antibody specifically precipitated a
fragment spanning the v5 exon and the upstream intron sequence
from the minigene pre-mRNA (compare lanes 1 and 2). Phorbol-
ester treatment of the cells for as little as ten minutes, which
induces ERK-mediated Sam68 phosphorylation ([19] and data
not shown), consistently led to a marked decrease in the amount of
precipitated fragment (lanes 2 and 3). This result indicates
interference with the occupancy of the RNA fragment by
Sam68. To further ascertain that the differences seen between
the samples are not caused by differential loss of precipitation
material during handling, we wished to amplify traces of RNA
bound unspecifically to the antibody and/or the agarose beads
used for precipitation. Therefore, we amplified a fragment of
GAPDH mRNA. This fragment was present at similar amounts in
the different samples, including the control antibody sample
(Figure 4B, lower panel), indicating no differential loss of material
between the specimens.
Taken together, the results on RNA binding obtained in vitro
and in vivo suggest that the Ras-signaling-induced phosphorylation
of Sam68 by ERK interferes with Sam68 binding to its elements
on pre-mRNA.
Sam68 and regulated pre-mRNA occupancy by U2AF
Given the interaction of Sam68 and U2AF65, binding of Sam68
might stabilize association of U2AF with pre-mRNA. If this were
true, the rapid release from RNA of Sam68 upon phorbol-ester
treatment of the cells, should result in decreased pre-mRNA
occupancy by U2AF65 in vivo. To test this prediction, we
performed RNP immunoprecipitation experiments using an anti-
Figure 3. Phosphorylation of Sam68 by ERK MAP-kinase impairs its
binding to RNA in vitro. (A) Immunoblotting of non-phosphorylated
(2) and ERK-phosphorylated (P) recombinant Sam68 preparations used
in (B). Phosphorylation of Sam68 at ERK target sites results in a
molecular weight shift (arrow) [19]. Black bar on the left indicates
marker band. (B) Electrophoretic mobility shift assay using RNA
oligonucleotide probes comprising the exonic or intronic Sam68
binding sites and different amounts of either non-phosphorylated (2)
or phosphorylated (P) recombinant Sam68.
doi:10.1371/journal.pone.0001418.g003
Figure 4. Signaling-induced interference with Sam68 binding to pre-
mRNA in vivo. (A) Detection of Sam68 binding to an endogenous CD44
pre-mRNA fragment (spanning the v5 exon and 100 bp upstream intron
sequence) in LB17 lymphoma cells by RNP immunoprecipitations. A
control antibody (CoAb) or an anti-Sam68 antibody were used for
precipitations. Lower panels show amplifications from the lysate used
as input for the precipitations. Bands correspond to the expected size of
228 bp. Positions of primers used for amplification are indicated as
arrowheads in scheme on top; Sam68 binding sites (black oval and box,
respectively), CD44 exons v4 and v5 (open boxes), intron (line). –RT
represents reactions without reverse transcriptase. (B) RNP immuno-
precipitations with either a control antibody (CoAb) or an anti-Sam68
antibody from lysates of LB17 lymphoma cells that were transfected
with the pETv5 minigene construct [23]. The cells were either left
untreated (2) or treated with 40 ng/ml of 12-o-tetradecanoylphorbol-
13-acetate (TPA) for 10 min. A fragment from the minigene pre-mRNA
spanning the v5 exon and 450 bp upstream intron sequence (In-v5) was
amplified using the primers indicated (scheme on top; symbols as in
panel A). Specific amplification of the minigene pre-mRNA is achieved
by the forward primer that is complementary to the deletion junction of
the v4 exon in the construct. To check for potential differential loss of
material during the precipitation and washing procedure, we moni-
tored the amounts of GAPDH mRNA unspecifically bound to the
antibody and/or the agarose beads (lower panel). Bands correspond to
the expected sizes of 600 bp (In-v5) and 278 bp (GAPDH). All PCR
amplifications were in linear phase as verified with different amounts of
cDNA.
doi:10.1371/journal.pone.0001418.g004
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fragments containing the CD44 v5 exon and the upstream intron
sequence (Figure 5A, lanes 1 and 2). Furthermore, phorbol-ester
treatment of the cells for ten minutes led to a marked reduction of
the fragments detectable in the U2AF immunoprecipitate
(Figure 5A, compare lanes 2 and 3). This finding supports the
idea that RNA-bound Sam68 can act as a stabilizing factor for
U2AF binding. To test this idea further, we examined if forced
expression of Sam68 can increase the occupancy of this pre-
mRNA region by U2AF65. Figure 5C shows that co-transfection
of a Sam68 expression vector led to an increase in the RNA
fragments precipitated with the anti-U2AF65 antibody when
compared to control-vector transfected cells (lanes 2 and 3).
Together with the GST pull-down and co-immunoprecipitation
data, these findings point to Sam68 as a factor that can stabilize
U2AF binding by protein-protein interaction in vivo. Moreover,
they suggest that Ras-signaling-induced phosphorylation of Sam68
interferes with binding of Sam68 to RNA, and may thus affect
splice site occupancy by U2AF65.
DISCUSSION
The binding of U2AF65 to the pyrimidine stretch of the 39 splice
site is a crucial step for exon definition and spliceosome assembly
in higher eukaryotes [6,10]. Alternatively spliced exons are often
preceded by a poor pyrimidine tract and their splicing is
dependent on exonic splice enhancers elements [11,12]. For some
of these exons, biochemical experiments have suggested the
recruitment of U2AF through interaction of its 35 kDa unit with
serine/arginine-rich (SR) domains of splice enhancer factors
(U2AF recruitment model) [13]. Notably, U2AF65 binds the
pre-mRNA only transiently in the course of spliceosome
formation. It dissociates from pre-mRNA in the first ATP-
dependent pre-spliceosome complex, followed by further spliceo-
some assembly [25,26].
Our data suggest that U2AF interacts with the signal-dependent
splice regulator Sam68 by protein-protein interaction and that
Sam68 can support binding of U2AF to pre-mRNA in vivo. The
two proteins appear to be part of a preformed, signal-responsive
complex over the CD44 v5 exon and the adjacent upstream
intronic sequences. The binding of Sam68 to its two binding sites
would be necessary for efficient complex formation, involving the
recruitment of U2AF, and so could determine the overall level of
v5 exon inclusion. Concomitantly, Sam68 is a factor targeted and
phosphorylated through the Ras-MAP-kinase signaling cascade, a
step necessary for the signal-induced splicing [19] and that results
in its release from RNA (this work). The rapid signal-dependent
decrease in Sam68 binding to pre-mRNA could allow to
reorganize the complex (that may still contain Sam68 but without
contacting RNA anymore) and thus initiate the induction process
of v5 exon splicing. However, given that the Sam68 binding-site
mutants are still inducible (see Figure 2C), Sam68 phosphorylation
appears to affect also other properties of the protein besides RNA
binding, conceivably as a result of a conformational change.
Interestingly, the signal-induced release of Sam68 from RNA was
paralleled by decreased U2AF65 occupancy of corresponding pre-
mRNA fragments in vivo. Together with the data showing that
phosphorylation of Sam68 by ERK MAP-kinase down-regulates the
ability of Sam68 to bind its cognate RNA elements, the results
suggest that Sam68 may so affect splice site occupancy of its binding
partner U2AF in a signal-dependent manner. This should result in
reorganization of factor binding to the 39 splice site and could allow
furtherspliceosomeassembly.OurdatadonotexcludethatU2AF65
itself may be an additional target for signal-dependent modification
of its binding to RNA. Thus, the findings link the release of U2AF
from pre-mRNA to a signaling cascade that activates splicing in
response to extracellular cues. The in vivo kinetics ofsplicing has been
suggested to be very rapid, at least for efficient constitutive splicing
events, showing halflives of 0.4–7.5 minutes [27]. We thus cannot
exclude that the release of U2AF from the corresponding CD44 pre-
mRNA region within minutes, observed here, is a consequence
rather than the cause of signal-induced splicing. However, our data
on the interaction of the two proteins, and on U2AF binding to pre-
mRNA supported by Sam68 in vivo, suggest that it is part of the
Sam68-dependent induction process. The requirements for the
releaseor displacementof U2AF fromsplicesitesduring spliceosome
assembly are only poorly understood. It should however depend on
the dynamic interaction with other proteins, like spliceosome-
associated proteins (SAPs) and U5 snRNP proteins, that appear to
replace it during further spliceosome assembly [25,26], or splice
enhancer proteins also involved in constitutive splicing. Thus, the
induced release of U2AF from pre-mRNA involving signal-
responsive partners like Sam68 could be a step to control
spliceosome assembly at regulated splice sites.
MATERIALS AND METHODS
Cell culture and transfections
LB17 2.3 murine T-lymphoma cells were grown as described
[23,28]. Transient transfections with the pETv5 minigene
construct [23] were performed with the polycationic SuperFect
reagent (Qiagen) according to the instructions of the manufactur-
er, using 5 mg of DNA. For Sam68 overexpression, 3 mg of pETv5
were cotransfected with with 2 mg of either pcDNA3-Sam68 [19]
or of the empty vector as a control.
GST pull-down assay
0.5–1 mg of GST-U2AF fusion proteins or of GST as a control were
incubated with 100 or 200 ng of recombinant His-Sam68 in 50 ml
Figure 5. Sam68 and pre-mRNA occupancy by U2AF. (A) Schematic
drawing of the examined CD44 minigene pre-mRNA region (CD44 exon
v5, open box; upstream intron, line; Sam68 binding sites, black oval and
box, respectively; arrows, PCR primer). (B) RNP immunoprecipitations
with an anti-U2AF65 antibody or a control antibody (CoAb) from lysates
of LB17 lymphoma cells that were transfected with the pETv5 minigene
construct containing CD44 exon v5. Cells were left either untreated (2)
or treated with phorbol ester (TPA). TPA treatment and RNP
immunoprecipitations were performed as described in legend to
Figure 4. (C) RNP immunoprecipitations of U2AF65 from LB17
lymphoma cells co-transfected with the pETv5 minigene construct
and either a Sam68 expression plasmid (+) or the empty expression
vector as a control (2). Bands correspond to the expected sizes of
600 bp (In-v5) and 278 bp (GAPDH). All PCR amplifications were in
linear phase as verified with different amounts of cDNA.
doi:10.1371/journal.pone.0001418.g005
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binding buffer containing 20 ml of a 50% slurry of glutathione
sepharose were added and reactions were rotated at room
temperature (RT) for 90 min. After washing three times with binding
buffer, precipitates were analysed by SDS-PAGE and immunoblot-
ting with the anti-Sam68 antibody C20 or the anti-GST antibody Z5
(both from Santa Cruz Biotechnology). GST-fusion proteins of
U2AF65andU2AF35wereexpressed inE.coliBL21fromconstructs
carrying corresponding human cDNAs (starting with the second
codon) in the Xho I site of pGEX-4T-3 (Amersham Pharmacia).
Fusion proteins were purified by the GST-purification module
(Amersham Pharmacia) according to the instructions of the
manufacturer. His-Sam68 was obtained as described below.
Co-immunoprecipitations
Cells were lysed in CoIP buffer (50 mM Tris-HCl pH 8.0,
100 mM NaCl, 0.5% NP40; supplemented with 0.1 mM DTT;
1 mM PMSF; 2 mg/ml Aprotinin and 2 mg/ml Leupeptin) and
the cleared lysate was incubated with a polyclonal rabbit anti-
Sam68 antibody (C20, Santa Cruz Biotechnology) bound to
protein A/G agarose at 4uC for 1h. For RNase treatment, 0.2 mg/
ml RNase A was added to the lysates 60 min prior to precipitation.
Precipitates were washed three times with CoIP buffer. After SDS-
PAGE, U2AF65 was detected by immunoblotting with a mouse
monoclonal anti-U2AF65 antibody (clone MC3; Sigma-Aldrich).
RNP immunoprecipitation
1–2610
7 cells were used for in vivo crosslinking using 0.1%
formaldehyde and lysed as described [24]. Crosslinked complexes
were solubilized and RNA was fragmented to a length of 400–600
nucleotides by sonification. Immunoprecipitations were performed
with protein A/G agarose coated with 2 mg of either the
polyclonal rabbit anti-Sam68 antibody C20 (Santa Cruz Biotech-
nology) and a polyclonal rabbit anti-GST antibody as a control, or
with a monoclonal mouse anti-U2AF65 antibody (MC3, Sigma-
Aldrich) and mouse IgG as a control, at RT for 90 min. Prior to
immunoprecipitation, protein A/G was incubated with 20 units of
RNasin (Promega) for 10 min. Immunoprecipitates were washed
four times with high-stringency RIPA buffer (50 mM Tris-HCl
pH 7.5, 1 M NaCl 1% NP40, 1% sodium deoxycholate, 0.1%
SDS, 1 mM EDTA, 1 M Urea, 0.2 mM PMSF). Precipitated
complexes were de-crosslinked in 100 ml 50 mM Tris-HCl
pH 7.0, 1% SDS, 5 mM EDTA, 10 mM DTT at 70uC for
45 min and RNA was extracted using RNAPure (Peqlab) followed
by DNase digestion. Half of the RNA was reverse transcribed
involving random priming. For amplification of the endogenous
CD44 pre-mRNA fragment (228 bp in length), primers hybridiz-
ing 60 bp upstream of the intronic Sam68 binding site (forward
primer; GCTTAGGCATAGAACCAGTAGA) and at the end of
CD44 exon v5 (reverse primer; TACTTGTGCTTGTAG-
CATGTGG) were used. For detecting the pre-mRNA fragment
from the pETv5 minigene (607 bp in length), a primer spanning
the deletion site of CD44 exon v4 was used as forward primer
(TCATTATGACAGTTGCCACCAG). Thirty and thitry-five
PCR cycles (95uC for 1 min; 55uC for 1 min; and 72uC for
1.5 min) were performed for amplification of fragments from the
endogenous CD44 gene and the transfected minigene, respective-
ly. PCRs for GAPDH (278 bp) were performed using the primers
AGACAGCCGCATCTTCTTGTGC and CTCCTGGAA-
GATGGTGATGG. Thirty cycles (95uC for 1 min; 55uC for
1 min; and 72uC for 1.5 min) were performed.
Electrophoretic mobility shift assay (EMSA)
EMSA reactions were performed as described [19] using radioac-
tively end-labeled RNA oligonucleotides and recombinant non-
phosphorylated His-Sam68 or His-Sam68 phosphorylated with
ERKMAP-kinaseinvitro.Oligonucleotide sequencescomprisingthe
exonic and intronic Sam68 binding sites were AUAGACAGAAU-
CAGCACCAGUGCUCAUGGAGAAAAUUGGACC and GAA-
GAAGAGGAUUAUUAAAGACUAUUUGAUUAGA, respec-
tively. His-tagged Sam68 was expressed from E.coli strain M15
from a pQE-32 construct (Qiagen) carrying the mouse Sam68
cDNA sequence. Purification of the protein was performed using
NI-NTA agarose (Qiagen). In vitro phosphorylation by ERK in the
presence of 1 mM ATP-cS was performed by four consecutive
reaction cycles using 200 units of activated recombinant ERK2
(New England Biolabs) as described [19]. We used 25 and 50 ng
recombinant Sam68 in the EMSA with the exonic probe and 175
and 250 ng with the intronic probe.
SUPPORTING INFORMATION
Figure S1
Found at: doi:10.1371/journal.pone.0001418.s001 (0.14 MB
DOC)
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